What is Prolacta Bioscience?
Founded in 1999 and headquartered in Duarte, California, Prolacta Bioscience is a privately held life sciences enterprise dedicated to advancing the science of human milk. As the world's leading hospital provider of 100% human milk-based nutritional products, the company occupies a critical niche in neonatal healthcare. By leveraging advanced processing technologies, Prolacta provides life-saving nutrition that significantly improves health outcomes for premature and critically ill infants. Their market position is defined by a unique combination of rigorous scientific research, proprietary manufacturing processes, and a deep integration into the neonatal intensive care unit (NICU) ecosystem, effectively bridging the gap between biological necessity and clinical application.
How much funding has Prolacta Bioscience raised?
Prolacta Bioscience has raised a total of $73.6M across 6 funding rounds:
Series A
$811K
Series B
$5M
Series C
$12M
Private Equity
$5.8M
Series D
$15M
Private Equity
$35M
Series A (2004): $811K, investors not publicly disclosed
Series B (2006): $5M led by Funk Ventures Capital, Arcturus Capital, Gideon Hixon Fund, and Mercury Fund
Series C (2007): $12M supported by Gideon Hixon Fund, Alta Partners, DFJ Frontier, Funk Ventures, and DFJ Mercury
Private Equity (2011): $5.8M, investors not publicly disclosed
Series D (2011): $15M backed by Health Evolution Partners
Private Equity (2016): $35M, investors not publicly disclosed
Key Investors in Prolacta Bioscience
Funk Ventures Capital
A multi-faceted private equity firm based in Los Angeles that provides value-add investments across technology, wellness, and business services sectors.
Arcturus Capital
A venture capital firm that specializes in financing new technologies developed within sponsored research laboratories and academic partnerships.
Alta Partners
A prominent healthcare and life sciences venture capital firm dedicated to supporting entrepreneurs in building impactful companies that enhance patient outcomes.
What's next for Prolacta Bioscience?
Looking ahead, the infusion of capital positions Prolacta Bioscience to further penetrate the global neonatal nutrition market. The company is expected to prioritize the expansion of its clinical research initiatives and the optimization of its supply chain to meet the increasing demand for human milk-based fortifiers. By maintaining a focus on high-impact, evidence-based nutritional interventions, Prolacta is well-positioned to navigate the complexities of the healthcare landscape. Future strategic efforts will likely center on scaling production capacity and fostering new partnerships with major hospital networks, ensuring that their specialized nutritional products remain accessible to the most vulnerable patient populations worldwide.
See full Prolacta Bioscience company page
